Japanese Panel Recommends Approval of Daiichi Sankyo COVID Vaccine Update – Kyodo

For help, call:

TOKYO (Reuters) – A Japanese health ministry committee on Monday approved an updated edition of Daiichi Sankyo’s COVID-19 vaccine, news firm Kyodo said.

The mRNA vaccine was first approved as a booster in August, becoming Japan’s first coronavirus vaccine. The vaccine has been updated to provide coverage against the XBB. 1. 5 Omicron subvariant, a quota that allows the Ministry of Health to purchase 1. 4 million doses.

The committee’s resolution paves the way for full government approval.

Separately, the panel’s approval of a self-powered mRNA coronavirus vaccine was submitted through Meiji Holdings’ pharmaceutical unit, Kyodo said.

In April, Meiji acquired the Japanese rights to the vaccine, developed through San Diego-based Arcturus Therapeutics.

(Reporting via Rocky Swift, editing via Louise Heavens)

Leave a Comment Cancel Reply